Predictors of Neurologic Outcome in Hypothermia After Cardiac Arrest
Ann Neurol 68:907-914, Fugate,J.E.,et al, 2010
Imaging Manifestations of Progressive Multifocal Leukoencephalopathy
Clinical Radiol 65:431-439, Shah,R.,et al, 2010
Treatment and Prognosis of Primary Central Nervous System Lymphoma
Up to Date Sept 2010, Hochberg,F.H.,et al, 2010
AIDS-Related Lymphomas: Epidemiology, Risk Factors, and Pathobiology
UpToDate, Sept, Kaplan, L.D.,et al, 2010
Primary Central Nervous System Post-Transplantation Lymphoproliferative Disorder
CANCER 16:863-870, Cavaliere, R.,et al, 2010
Acute Toxoplasmosis Infection in a Patient with Ankylosing Spondylitis Treated with Adalimumab: A Case Report
Reumatismo 62:283-285, Azevedo V.F., et al, 2010
Multiple Ring-Enhancing Lesions of the Brain
J Postgrad Med 56:307-316, Garg, R.K. & Sinha, M.K., 2010
Isolated Vein Thrombosis of the Posterior Fossa Presenting as Localized Cerebellar Venous Infarctions or Hemorrhages
Stroke 41:2358-2361, Ruiz-Sandoval, J.L.,et al, 2010
Neuro-Lyme Disease: MR Imaging Findings
Radiol 253:167-173, Agarwal, R. & Sze, G., 2009
Long-Term Course of Demyelinating Neuropathies Occurring During Tumor Necrosis Factor-a-Blocker Therapy
JAMA Neurol 66:490-497, Lozeron, P.,et al, 2009
May-Thurner Syndrome in Patients with Cryptogenic Stroke and Patent Foramen Ovale
Stroke 40:1502-1504, Kiernan, T.J.,et al, 2009
Rheumatoid Leptomeningitis: Rare Complication of Rheumatoid Arthritis
Clin Rheumatol 28:1117-1119, Koide, R.,et al, 2009
Hyperdense or Pseudohyperdense MCA Sign, A Damocles Sword?
Neurol 72:116-117, Jha,B. & Kothari,M., 2009
Plasmablastic Lymphoma: CNS Involvement, Coexistence of Other Malignancies, Possible Viral Etiology, and Dismal Outcome
Ann Hematol 88:351-358, Ustun, C.,et al, 2009
MRI Findings Associated With Acute Liver Failure
Neurol 72:2130-2131, Fridman,V.,et al, 2009
Lateral Sinus Thrombosis: Complication of Minor Head Injury
Int J Pediatr Otorhinolaryngol 73:629-635, Nehme, J.,et al, 2009
Herpes Simplex Encephalitis during Treatment with Tumor Necrosis Factor- Inhibitors
CID 49:924-927, Bradford, R.D.,et al, 2009
Reversible Extralimbic Paraneoplastic Encephalopathies with Large Abnormalities on Magnetic Resonance Images
Arch Neurol 66:268-271, McKeon,A.,et al, 2009
Spontaneous Primary Intraventricular Hemorrhage in Adults: Clinical Data, Etiology and Outcome
Turkish Neurosurgery 19:338-344, Giray, S.,et al, 2009
N-Methyl-D-Aspartate Receptor Antibodies in Pediatric Dyskinetic Encephalitis Lethargica
Ann Neurol 66:704-709, Dale,R.,et al, 2009
Aspirin vs Anticoagulation in Carotid Artery Dissection: A Study of 298 Patients
Neurol 72:1810-1815,1800, Georgiadis,D.,et al, 2009
Statin Therapy After First Stroke Reduces 10-Year Stroke Recurrence and Improves Survival
Neurol 72:1816-1822, Milionis,H.J.,et al, 2009
Intravenous Thrombolysis in Stroke Attributable to Cervical Artery Dissection
Stroke 40:37772-3776, Engelter,S.,et al, 2009
Evaluation and Treatment of Inflammatory Myopathies
JNNP 80:1060-1068, Amato,A. &Barohn,R.J., 2009
A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinsons Disease
NEJM 361:1268-1278, 1304, Olanow,C.,et al, 2009
Dabigatran Versus Warfarin in Patients with Atrial Fibrillation
NEJM 361:1139-1151, 1200, Connolly,S.,et al, 2009
Treatment of Neuromyelitis Optica with Mycophenolate Mofetil
Arch Neurol 66:1128-1133, Jacob,A.,et al, 2009
Progressive Multifocal Leukoencephalopathy After Natalizumab Monotherapy
NEJM 361:1081-1087, Linda,H.,et al, 2009
Asymptomatic Reactivation of JC Virus in Patients Treated with Natalizumab
NEJM 361:1067-1074, Chen,Y.,et al, 2009
Treatment of Progressive Multifocal Leukoencephalopathy Associated with Natalizumab
NEJM 361:1075-1080, Wenning,W.,et al, 2009
Brainstem Lesions in Diffusion Sequences of MRI Can be Reversible After Arterial Recanalization
Neurol 73:813-815, Vilas,D., 2009
Combined Corticosteroid and Antiviral Treatment for Bell Palsy: A Systematic Review and Meta-analysis
JAMA 302:985-993, 1003, Almeida,J.,et al, 2009
Outcome of Symptomatic Intracranial Atherosclerotic Disease
Stroke 40:2983-2987, Samaniego,E.,et al, 2009
Angiotensin Receptor Blockers Should Be Regarded as First-Line Drugs for Stroke Prevention in Both Primary and Secondary Prevention Settings: No
Stroke 40:3161-3162, 3163, Strauss,M. &Hall,A., 2009
Angiotensin Receptor Blockers Should Be Regarded as First-Line Drugs for Stroke Prevention in Both Primary and Secondary Prevention Settings: Yes
Stroke 40:3159-3160, 3163, Hackam,D., 2009
Primary Central Nervous System Lymphoma in a Patient Treated with Natalizumab
Ann Neurol 66:403-406, 261, 262, Schweikert,A.,et al, 2009
Natalizumab and Central Nervous System Lymphoma: No Clear Association
Ann Neurol 66:261-262, Bozic,C.,et al, 2009
Natalizumab: A Double-Edged Sword?
Ann Neurol 66:262-263, DeAngelis,L., 2009
Medial Medullary Infarction: Clinical, Imaging, and Outcome Study in 86 Consecutive Patients
Stroke 40:3221-3225, Kim,J. &Han,Y., 2009
Intraventricular Fibrinolysis and Lumbar Drainage for Ventricular Hemorrhage
Stroke 40:3275-3280, Staykov,D.,et al, 2009
Transcranial Ultrasound in Clinical Sonothrombolysis (TUCSON) Trial
Ann Neurol 66:28-38, Molina,C.A.,et al, 2009
Lamotrigine Kinetics Within the Menstrual Cycle, After Menopause, and with Oral Contraceptives
Neurol 73:1388-1393, Wegner,I.,et al, 2009
Statin Treatment and Stroke Outcome in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial
Stroke 40:3526-3531,3413, Goldstein,L.,et al, 2009
Interventions in the Management of Serum Lipids for Preventing Stroke Recurrence
Stroke 40:e622-e623, Manktelow,B. &Potter,J., 2009
Hearing Improvement After Bevacizumab in Patients with Neurofibromatosis Type 2
NEJM 361:358-367, Plotkin,S.R.,et al, 2009
Recurrent Cerebral Ischemia in Medically Treated Patent Foramen Ovale: A Meta-Analysis
Neurol 73:89-97,84, Almekhlafi,M.A.,et al, 2009
Frequency, Characteristics, and Risk Factors for Amiodarone Neurotoxicity
Arch Neurol 66:865-869, Orr,C.F. &Ahlskog,E., 2009
Intraarterial Thrombolysis Within the First Three Hours After Acute Ischemic Stroke in Selected Patients
Stroke 40:2611-2612,2615, Moonis,M., 2009
Is Intraarterial tPA Within 3 Hours the Treatment of Choice for Selected Stroke Patients? No
Stroke 40:2613-2614,2615, Lindley,R.I., 2009
Number Needed to Treat to Benefit and to Harm for Intravenous Tissue Plasminogen Activator Therapy in the 3- to 4.5-Hour Window: Joint Outcome Table Analysis of the ECASS 3 Trial
Stroke 40:2433-2437,2295, Saver,J.L.,et al, 2009